| abstract |
The present invention is a polymer with controlled end group stoichiometry, comprising a surface layer, at least one sub-surface layer, and a first end group that is the residue of a pharmaceutically active agent, derivative or precursor thereof. And a polymer comprising at least two end groups comprising a second end group selected to modify the pharmacokinetics of the pharmaceutically active agent and / or polymer (in this case, end group stoichiometry is defined as end group stoichiometry) Number and type). |